Advertisement

Japanese Journal of Ophthalmology

, Volume 60, Issue 2, pp 72–77 | Cite as

Association between glaucoma eye drops and hyperemia

  • Masahide YanagiEmail author
  • Yoshiaki Kiuchi
  • Yuki Yuasa
  • Tsuyoshi Yoneda
  • Tamaki Sumi
  • Yasuhiro Hoshikawa
  • Masahiko Kobayashi
  • Atsuki Fukushima
Clinical Investigation

Abstract

Purpose

We used an image analysis software program to quantitatively investigate conjunctival injection in patients treated with eye drops for glaucoma.

Methods

We compared 169 patients (89 men and 80 women) with a diagnosis of glaucoma. Photographs of the conjunctiva were taken on the temporal side of each patient’s right eye using a slit lamp. We determined the mean pixel frequencies of the conjunctival blood vessels from the photographs.

Results

The ocular hyperemia of the patients being treated with prostaglandins was more severe than that of the patients being treated with beta-blockers or no eye drops. In multiple comparisons of each of the eye drops, the control group had a significantly lower degree of hyperemia than did the patients being treated with each of the various prostaglandin analogs (latanoprost, travoprost, tafluprost, and bimatoprost). Among the patients receiving prostaglandin, the percentage of those with hyperemia was highest in the bimatoprost users, followed in order by the travoprost, latanoprost, and tafluprost users. However, no significant differences were found among the different prostaglandin analogs in terms of the percentage of patients with hyperemia.

Conclusion

Our software program may be useful for evaluating the hyperemic effects of eye drops used for glaucoma. The particular type of prostaglandin analog seems to determine the level of conjunctival hyperemia during ocular hypotensive medical treatment.

Keywords

Conjunctival injection Glaucoma Hyperemia Eye drops 

Notes

Conflicts of interest

M. Yanagi, Lecture fees (Santen); Y. Kiuchi, Commercial sponsor (Alcon, Pfizer, Santen, Senju); Y. Yuasa, None; T. Yoneda, Lecture fees (Kowa); T. Sumi, Lecture fees (Santen); Y. Hoshikawa, Employee (Nidek); M. Kobayashi, Employee (Nidek); A. Fukushima, Consultant fees (Alcon, Kissei, Kobayashi, Kowa, Kyowa-Kirin, Ohtsuka, Santen, Senju, Tanabe-Mitsubishi), P (License for Hyperemia-analyzing software).

References

  1. 1.
    Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: proyecto VER. Arch Ophthalmol. 2001;119:1819–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Tielsch JM, Katz J, Quigley HA, Javitt JC, Sommer A. Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey. Ophthalmology. 1995;102:48–53.CrossRefPubMedGoogle Scholar
  3. 3.
    Honrubia F, Garcia-Sanchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009;93:316–21.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Friedman DS, Hahn SR, Gelb L, Tan J, Shah SN, Kim EE, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the glaucoma adherence and persistency study. Ophthalmology. 2008;115:1320–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Park MH, Kang KD, Moon J. Noncompliance with glaucoma medication in Korean patients: a multicenter qualitative study. Jpn J Ophthalmol. 2013;57:47–56.CrossRefPubMedGoogle Scholar
  6. 6.
    Lewis RA, Katz GJ, Weiss MJ, Landry TA, Dickerson JE, James JE, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98–103.CrossRefPubMedGoogle Scholar
  7. 7.
    Konstas AG, Kozobolis VP, Katsimpris IE, Boboridis K, Koukoula S, Jenkins JN, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology. 2007;114:653–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Garcia-Feijoo J, Martinez-de-la-Casa JM, Castillo A, Mendez C, Fernandez-Vidal A, Garcia-Sanchez J. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin. 2006;22:1689–97.CrossRefPubMedGoogle Scholar
  9. 9.
    Chen MJ, Chen YC, Chou CK, Hsu WM. Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma. J Ocul Pharmacol Ther. 2006;22:449–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Parmaksiz S, Yuksel N, Karabas VL, Ozkan B, Demirci G, Caglar Y. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006;16:73–80.PubMedGoogle Scholar
  11. 11.
    Yoneda T, Sumi T, Takahashi A, Hoshikawa Y, Kobayashi M, Fukushima A. Automated hyperemia analysis software: reliability and reproducibility in healthy subjects. Jpn J Ophthalmol. 2012;56:1–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Kobayashi H, Kobayashi K. A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect. J Glaucoma. 2011;20:3–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123:186–92.CrossRefPubMedGoogle Scholar
  14. 14.
    Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205–15.CrossRefPubMedGoogle Scholar
  15. 15.
    Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Davis TL, Sharif NA. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J Ocul Pharmacol Ther. 1999;15:323–36.CrossRefPubMedGoogle Scholar
  18. 18.
    Hellberg MR, Sallee VL, McLaughlin MA, Sharif NA, Desantis L, Dean TR, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001;17:421–32.CrossRefPubMedGoogle Scholar
  19. 19.
    Ota T, Murata H, Sugimoto E, Aihara M, Araie M. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest Ophthalmol Vis Sci. 2005;46:2006–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Remis LL, Epstein DL. Treatment of glaucoma. Annu Rev Med. 1984;35:195–205.CrossRefPubMedGoogle Scholar
  21. 21.
    Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2003;19:23–35.CrossRefPubMedGoogle Scholar
  22. 22.
    Camras CB, The United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. Ophthalmology. 1996;103:138–47.CrossRefPubMedGoogle Scholar
  23. 23.
    Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension; a 12-week study. Arch Ophthalmol. 1996;114:929–32.CrossRefPubMedGoogle Scholar
  24. 24.
    Martin XD, Rabineau PA. Vasoconstrictive effect of topical timolol on human retinal arteries. Graefes Arch Clin Exp Ophthalmol. 1989;227:526–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012;13:723–45.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2016

Authors and Affiliations

  • Masahide Yanagi
    • 1
    Email author
  • Yoshiaki Kiuchi
    • 1
  • Yuki Yuasa
    • 1
  • Tsuyoshi Yoneda
    • 2
  • Tamaki Sumi
    • 2
  • Yasuhiro Hoshikawa
    • 3
  • Masahiko Kobayashi
    • 3
  • Atsuki Fukushima
    • 2
  1. 1.Department of Ophthalmology and Visual SciencesHiroshima UniversityHiroshimaJapan
  2. 2.Department of Ophthalmology and Visual ScienceKochi UniversityNankokuJapan
  3. 3.NIDEK CO. LTDGamagoriJapan

Personalised recommendations